Researchers have developed experimental drugs that prompt mitochondria in human cells to increase calorie burning, potentially paving the way for new obesity treatments and improved metabolic health. The study was led by Associate Professor Tristan Rawling from the University of Technology Sydney (UTS) and published in Chemical Science, the flagship journal of the UK Royal Society of Chemistry.
Obesity remains a significant global health issue and is associated with diseases such as diabetes and cancer. Existing medications for obesity often require injections and may cause side effects, creating a need for safer alternatives.
The research team from UTS and Memorial University of Newfoundland focused on "mitochondrial uncouplers," molecules that cause cells to burn energy less efficiently, releasing excess fuel as heat rather than converting it into usable energy.
"It's been described as a bit like a hydroelectric dam. Normally, water from the dam flows through turbines to generate electricity. Uncouplers act like a leak in the dam, letting some of that energy bypass the turbines, so it is lost as heat, rather than producing useful power," according to the researchers.
Historically, compounds inducing mitochondrial uncoupling were discovered about 100 years ago but proved highly toxic. Associate Professor Rawling explained: "During World War I, munitions workers in France lost weight, had high temperatures and some died. Scientists discovered this was caused by a chemical used at the factory, called 2,4-Dinitrophenol or DNP."
"DNP disrupts mitochondrial energy production and increases metabolism. It was briefly marketed in the 1930's as one of the first weight-loss drugs. It was remarkably effective but was eventually banned due to its severe toxic effects. The dose required for weight loss and the lethal dose are dangerously close," he said.
In their recent work, researchers engineered safer "mild" mitochondrial uncouplers by carefully modifying chemical structures to control how much they increased cellular energy use. Some experimental drugs boosted mitochondrial activity without harming cells or interfering with ATP production; others produced similar risks seen with older compounds.
This approach helped scientists understand why certain molecules were less harmful. Mild mitochondrial uncouplers slow down processes enough for cells to manage safely, reducing adverse effects.
These milder agents also help decrease oxidative stress within cells—a factor that could enhance metabolic health and potentially offer anti-aging benefits or protection against neurodegenerative diseases like dementia.
While these findings are preliminary, they provide a foundation for developing new drugs designed to induce mild mitochondrial uncoupling safely.
